Navarixin is primarily used in the field of medical research and therapy development, particularly in the treatment of inflammatory diseases and certain types of cancer. It functions as a selective antagonist of the CXCR1 and CXCR2 chemokine receptors, which play a significant role in the recruitment of immune cells to sites of inflammation. By blocking these receptors, Navarixin helps reduce inflammation and can potentially slow the progression of diseases where inflammation is a key factor, such as chronic obstructive pulmonary disease (COPD) and rheumatoid arthritis. Additionally, its ability to inhibit these receptors makes it a candidate for research in cancer therapy, as it may help in controlling tumor growth and metastasis by limiting the migration of cancer cells and the formation of new blood vessels that supply tumors.